Serum Biomarker Immunoassay for Inner Ear Disorder Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing inner ear disorders such as hearing loss and vertigo are inadequate for early detection, leading to delayed intervention and increased morbidity and financial burden, as they rely on audiometric testing that can only measure hearing loss after it becomes measurable.
Innovation Solution
The use of serum or plasma biomarkers like otolin-1, prestin, otoconin-90, and oncomodulin to detect inner ear disorders through immunoassays, allowing for early detection before hearing loss becomes measurable, by measuring their levels in samples and comparing them to reference populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If audiometric testing is used for diagnosis, then hearing loss can be measured, but detection is delayed until loss becomes measurable
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels (otolin-1, prestin, otoconin-90, oncomodulin) in serum or plasma samples to detect inner ear damage before it manifests as measurable hearing loss. This allows early identification of at-risk individuals before conventional audiometric testing would show abnormalities, enabling preventive intervention.
2Loss of time
If early detection methods are implemented, then intervention timing is improved, but diagnostic complexity increases
Solution Approach 1:
The patent replaces the mechanical/acoustic system of audiometric testing with a biochemical analysis system. Instead of measuring sound response through complex auditory pathways, the invention uses immunoassays to detect specific inner ear biomarkers in blood samples, simplifying the diagnostic approach while enabling earlier detection.
3Measurement precision
If biomarker analysis is used, then early detection is enabled, but measurement methodology becomes more complex
Solution Approach 1:
The patent uses serum or plasma as an intermediary medium to access inner ear biomarkers non-invasively. These biomarkers (otolin-1, prestin, otoconin-90, oncomodulin) serve as mediators that reflect inner ear health status in the bloodstream, allowing indirect but accurate measurement of inner ear condition without direct access to the inner ear structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early identification of inner ear disorders, allowing for timely intervention and reducing the risk of progression to disabling hearing loss and tinnitus, thereby decreasing the societal burden and improving quality of life.
Implementation Method 1
The use of serum or plasma biomarkers like otolin-1, prestin, otoconin-90, and oncomodulin to detect inner ear disorders through immunoassays
Data Source
AI summary
Described herein are compositions and methods for the detection of inner ear disorders such as balance disorders and hearing disorders resulting from acoustic injury, exposure to ototoxins, head trauma or viral illness. Specifically, otolin-1 and prestin have been verified as inner-ear specific biomarkers suitable for the detection of inner ear disorders.